Long-term use of adalimumab as monotherapy after attainment of low disease activity with adalimumab plus methotrexate in patients with rheumatoid arthritis

Схожие документы

• Achieving comprehensive disease control in patients with early and established rheumatoid arthritis treated with adalimumab plus methotrexate versus methotrexate alone
  по: Keystone, Edward C, et al.
  Опубликовано: (2017)
• Testing treat-to-target outcomes with initial methotrexate monotherapy compared with initial tumour necrosis factor inhibitor (adalimumab) plus methotrexate in early rheumatoid arthritis
  по: Kavanaugh, Arthur, et al.
  Опубликовано: (2018)
• Treatment efficacy and methotrexate-related toxicity in patients with rheumatoid arthritis receiving methotrexate in combination with adalimumab
  по: Burmester, Gerd R, et al.
  Опубликовано: (2017)
• Predictors of disease activity and structural progression after treatment with adalimumab plus methotrexate or continued methotrexate monotherapy in patients with early rheumatoid arthritis and suboptimal response to methotrexate
  по: Smolen, Josef S, et al.
  Опубликовано: (2018)
• Safety and effectiveness of upadacitinib or adalimumab plus methotrexate in patients with rheumatoid arthritis over 48 weeks with switch to alternate therapy in patients with insufficient response
  по: Fleischmann, Roy M, et al.
  Опубликовано: (2019)